Victoria Tear

668 total citations
9 papers, 34 citations indexed

About

Victoria Tear is a scholar working on Epidemiology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Victoria Tear has authored 9 papers receiving a total of 34 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Epidemiology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Molecular Biology. Recurrent topics in Victoria Tear's work include Respiratory viral infections research (5 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (3 papers) and Microbial metabolism and enzyme function (2 papers). Victoria Tear is often cited by papers focused on Respiratory viral infections research (5 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (3 papers) and Microbial metabolism and enzyme function (2 papers). Victoria Tear collaborates with scholars based in United Kingdom, United States and Serbia. Victoria Tear's co-authors include Phillip Monk, Rona Beegan, Christopher E. Brightling, Stephen T. Holgate, Tom Wilkinson, J. Brookes, M Mańkowski, Sarah Dudley, Felicity Gabbay and Sarah Hrebien and has published in prestigious journals such as Respiratory Research, Open Forum Infectious Diseases and ERJ Open Research.

In The Last Decade

Victoria Tear

9 papers receiving 33 citations

Peers

Countries citing papers authored by Victoria Tear

Since Specialization

Citations

This map shows the geographic impact of Victoria Tear's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Victoria Tear with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Victoria Tear more than expected).

Fields of papers citing papers by Victoria Tear

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Victoria Tear. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Victoria Tear. The network helps show where Victoria Tear may publish in the future.

Co-authorship network of co-authors of Victoria Tear

This figure shows the co-authorship network connecting the top 25 collaborators of Victoria Tear. A scholar is included among the top collaborators of Victoria Tear based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Victoria Tear. Victoria Tear is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPD 2024 ·Respiratory Research ·Phillip Monk, J. Brookes, Victoria Tear, (unknown), (unknown), M Mańkowski, Michael G. Crooks, Dave Singh, Rekha Chaudhuri, Brian Leaker, (unknown), (unknown), Sarah Dudley, Felicity Gabbay, Stephen T. Holgate, Ratko Djukanović, Tom Wilkinson	5
2	Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study 2022 ·ERJ Open Research ·Phillip Monk, J. Brookes, Victoria Tear, (unknown), M Mańkowski, (unknown), Michael G. Crooks, Davinder Dosanjh, Monica Kraft, Christopher E. Brightling, Felicity Gabbay, Stephen T. Holgate, Ratko Djukanović, Tom Wilkinson	11
3	SPRINTER: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Determine the Efficacy and Safety of Inhaled Interferon Beta-1a (SNG001) for the Treatment of Patients Hospitalised Due to COVID-19 (NCT04732949) 2022 ·Phillip Monk, J. Brookes, Victoria Tear, (unknown), M Mańkowski, Monica Kraft, Christopher E. Brightling, Felicity Gabbay, Stephen T. Holgate, Ratko Djukanović, Tom Wilkinson	1
4	LB1533. Impact of Treatment of Hospitalised COVID-19 Patients With Inhaled Interferon Beta-1a (SNG001) on Long COVID Symptoms: Results From the SPRINTER trial 2022 ·Open Forum Infectious Diseases ·Phillip Monk, Rachael A Evans, Victoria Tear, J. Brookes, (unknown), M Mańkowski, Ratko Djukanović, Stephen T. Holgate, Christopher E. Brightling, Tom Wilkinson	2
5	Upregulation of Antiviral Biomarkers in Sputum Cells Following Administration of Inhaled Interferon Beta to Patients with COPD 2019 ·Phillip Monk, (unknown), (unknown), Rona Beegan, (unknown), Victoria Tear	2
6	Antiviral biomarkers are upregulated in sputum cells following administration of inhaled interferon beta to COPD patients 2019 ·(unknown), (unknown), Rona Beegan, Victoria Tear, Phillip Monk	6
7	Evaluation of novel LOXL2-selective inhibitors in models of pulmonary fibrosis 2017 ·(unknown), Victoria Tear, (unknown), (unknown), James S. Murphy, Chiko Shimbori, (unknown), (unknown), Ehab Ayaub, Mark G. Jones, Donna E. Davies, Wolfgang Jarolimek, Kjetil Ask, Jack Gauldie, Martin Kolb, Phillip Monk	2
8	Inhibition of collagen cross-links by novel LOXL2 selective inhibitors in an in-vitro model of fibroblastic foci of IPF 2016 ·(unknown), (unknown), Victoria Tear, Mark G. Jones, Donna E. Davies, (unknown), Wolfgang Jarolimek, Phillip Monk	1
9	Effect of inhaled SNG001 (interferon-beta 1a) on sputum and blood antiviral biomarkers following a respiratory virus infection in asthmatic subjects 2013 ·Christine B. Boxall, Sarah Dudley, Rona Beegan, Victoria Tear, Sarah Hrebien, (unknown), Phillip Monk	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact